News in brief

GSK signs R&D agreement with India-based CRO Syngene

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)
Syngene International has signed a multiyear agreement with GSK through which the companies will focus on accelerating the discovery of new drug candidates using the CRO’s discovery services platforms.

The contract research organization (CRO) Syngene International employs more than 3,100 scientists in India. As per the agreement, the company’s scientists will work with GlaxoSmithKline's (GSK) global R&D teams on discovery research projects.

The aim is to identify new drug candidates “with the potential to address some of the world’s most pressing healthcare needs,”​ according to the company.

To help achieve this goal, Syngene will establish a customized discovery research laboratory to support projects across several therapeutic areas. 

Following the announcement, the Indian firm’s shares went up 3.9% to 588.05 rupees​.

GSK is not providing any additional comment on the agreement at this time.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars